Logo image of CGC

CANOPY GROWTH CORP (CGC) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:CGC - CA1380357048 - Common Stock

1.23 USD
-0.06 (-4.65%)
Last: 1/9/2026, 4:06:08 PM
1.22 USD
-0.01 (-0.81%)
After Hours: 1/9/2026, 4:06:08 PM

CGC Key Statistics, Chart & Performance

Key Statistics
Market Cap453.21M
Revenue(TTM)278.61M
Net Income(TTM)-385.85M
Shares368.46M
Float341.58M
52 Week High2.9
52 Week Low0.77
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-2.03
PEN/A
Fwd PEN/A
Earnings (Next)02-05 2026-02-05/bmo
IPO2010-06-04
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


CGC short term performance overview.The bars show the price performance of CGC in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 10

CGC long term performance overview.The bars show the price performance of CGC in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of CGC is 1.23 USD. In the past month the price increased by 14.16%. In the past year, price decreased by -47.35%.

CANOPY GROWTH CORP / CGC Daily stock chart

CGC Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 48.37 1.01T
JNJ JOHNSON & JOHNSON 19.69 492.44B
MRK MERCK & CO. INC. 12.55 274.34B
PFE PFIZER INC 7.96 144.87B
BMY BRISTOL-MYERS SQUIBB CO 8.52 113.72B
ZTS ZOETIS INC 20.06 56.04B
RPRX ROYALTY PHARMA PLC- CL A 9.77 23.19B
VTRS VIATRIS INC 5.48 14.70B
ELAN ELANCO ANIMAL HEALTH INC 24.45 11.66B
AXSM AXSOME THERAPEUTICS INC N/A 8.54B
BLTE BELITE BIO INC - ADR N/A 5.53B
CRNX CRINETICS PHARMACEUTICALS IN N/A 5.05B

About CGC

Company Profile

CGC logo image Canopy Growth Corp. engages in the production, distribution, and sale of cannabis and cannabinoid-based products for both adult-use and medical purposes. The company is headquartered in Smiths Falls, Ontario and currently employs 960 full-time employees. The company went IPO on 2010-06-04. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. The firm delivers innovative products from owned and licensed brands, including Tweed, 7ACRES, DOJA, Deep Space, and Claybourne, as well as category defining vaporization devices by Storz & Bickel. Its segments include Canada cannabis, and Storz & Bickel. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. Its Storz & Bickel segment includes the production, distribution, and sale of vaporizers. In addition, it serves medical cannabis patients globally with principal operations in Canada, Europe and Australia.

Company Info

CANOPY GROWTH CORP

1 Hershey Dr

Smiths Falls ONTARIO K7A0A8 CA

CEO: David Klein

Employees: 1029

CGC Company Website

CGC Investor Relations

Phone: 18555589333

CANOPY GROWTH CORP / CGC FAQ

Can you describe the business of CANOPY GROWTH CORP?

Canopy Growth Corp. engages in the production, distribution, and sale of cannabis and cannabinoid-based products for both adult-use and medical purposes. The company is headquartered in Smiths Falls, Ontario and currently employs 960 full-time employees. The company went IPO on 2010-06-04. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. The firm delivers innovative products from owned and licensed brands, including Tweed, 7ACRES, DOJA, Deep Space, and Claybourne, as well as category defining vaporization devices by Storz & Bickel. Its segments include Canada cannabis, and Storz & Bickel. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. Its Storz & Bickel segment includes the production, distribution, and sale of vaporizers. In addition, it serves medical cannabis patients globally with principal operations in Canada, Europe and Australia.


What is the stock price of CANOPY GROWTH CORP today?

The current stock price of CGC is 1.23 USD. The price decreased by -4.65% in the last trading session.


Does CGC stock pay dividends?

CGC does not pay a dividend.


How is the ChartMill rating for CANOPY GROWTH CORP?

CGC has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Where is CANOPY GROWTH CORP (CGC) stock traded?

CGC stock is listed on the Nasdaq exchange.


How is the market expecting CGC stock to perform?

13 analysts have analysed CGC and the average price target is 2.81 USD. This implies a price increase of 128.62% is expected in the next year compared to the current price of 1.23.


Can you provide the upcoming earnings date for CANOPY GROWTH CORP?

CANOPY GROWTH CORP (CGC) will report earnings on 2026-02-05, before the market open.


CGC Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to CGC. When comparing the yearly performance of all stocks, CGC is a bad performer in the overall market: 88.78% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

CGC Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to CGC. While CGC seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CGC Financial Highlights

Over the last trailing twelve months CGC reported a non-GAAP Earnings per Share(EPS) of -2.03. The EPS increased by 58.25% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -36.07%
ROE -52.42%
Debt/Equity 0.33
Chartmill High Growth Momentum
EPS Q2Q%99.32%
Sales Q2Q%5.86%
EPS 1Y (TTM)58.25%
Revenue 1Y (TTM)-0.67%

CGC Forecast & Estimates

13 analysts have analysed CGC and the average price target is 2.81 USD. This implies a price increase of 128.62% is expected in the next year compared to the current price of 1.23.

For the next year, analysts expect an EPS growth of 94.86% and a revenue growth 2.14% for CGC


Analysts
Analysts47.69
Price Target2.81 (128.46%)
EPS Next Y94.86%
Revenue Next Year2.14%

CGC Ownership

Ownership
Inst Owners11.18%
Ins Owners0.18%
Short Float %9.09%
Short Ratio0.91